Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Porcine Parvovirus Vaccine, Inactivated (Strain NJ) is a veterinary vaccine developed by Liaoning Yikang Biological Co., Ltd. to prevent Porcine parvovirus (PPV) infection in swine. PPV is a significant pathogen responsible for reproductive failure in pigs, often manifesting as SMEDI syndrome (stillbirth, mummification, embryonic death, and infertility). The vaccine utilizes an inactivated NJ strain of the virus to induce active immunity and stimulate the production of protective antibodies in the host. By preventing PPV infection, the vaccine helps ensure the reproductive health and productivity of breeding herds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Porcine parvovirus vaccine, inactivated (strain NJ).